Related Experiment Video
Updated: Jun 14, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption
1Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, Utah 84112-5820, USA. luckwangyuwei@gmail.com
Purpose:
To demonstrate the ability of small interfering (si)RNA targeting the cell receptor, RANK, to control osteoclast function in cultures of both primary and secondary osteoclasts and their precursor cells.
Methods:
siRNA targeting RANK was transfected into both RAW264.7 and primary bone marrow cell cultures. RANK knock-down by siRNA and functional inhibition were assessed in both mature osteoclast and their precursor cell cultures. RANK mRNA message and protein expression after the transfections were analyzed by PCR and Western blot, respectively. Off-target effects were assessed. The inhibition of osteoclast formation was evaluated using tartrate-resistant acid phosphatase (TRAP) assay, and subsequent bone resorption was determined by resorption pit assay.
Results:
Both osteoclasts and osteoclast precursors can be targeted by siRNA in serum-containing media. Delivery of siRNA targeting RANK to both RAW 264.7 and primary bone marrow cell cultures produces short term repression of RANK expression without off-targeting effects, and significantly inhibits both osteoclast formation and bone resorption. Moreover, data support successful RANK knock-down by siRNA specifically in mature osteoclast cultures.
Conclusions:
RANK is demonstrated to be an attractive target for siRNA control of osteoclast activity, with utility for development of new therapeutics for low bone mass pathologies or osteoporosis.
Insights
Small interfering RNA (siRNA) targeting RANK effectively inhibits osteoclast formation and bone resorption. This demonstrates siRNA
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Osteoclasts are crucial for bone remodeling.
- Dysregulated osteoclast activity contributes to bone pathologies.
- Targeting cell surface receptors offers therapeutic potential.
Purpose of the Study:
- To evaluate the efficacy of small interfering RNA (siRNA) targeting the Receptor Activator of Nuclear Factor kappa-B (RANK) in controlling osteoclast function.
- To assess siRNA's ability to inhibit osteoclast formation and bone resorption in both primary and precursor cell cultures.
Main Methods:
- Transfection of siRNA targeting RANK into RAW264.7 and primary bone marrow cells.
- Assessment of RANK knockdown via PCR and Western blot.
- Evaluation of osteoclast formation using TRAP assay and bone resorption assays.
Main Results:
- siRNA targeting RANK successfully repressed RANK expression in osteoclast precursors and mature osteoclasts without off-targeting effects.
- Significant inhibition of osteoclast formation and bone resorption was observed.
- siRNA demonstrated efficacy in serum-containing media.
Conclusions:
- RANK is a viable molecular target for siRNA-mediated control of osteoclast activity.
- siRNA targeting RANK holds promise for developing novel therapeutics for osteoporosis and low bone mass conditions.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Remodeling
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Remodeling and Repair
Skeleton and Calcium Homeostasis
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
